Quantcast

Latest Receptor Stories

2014-07-07 04:20:43

LONDON and BOSTON, July 7, 2014 /PRNewswire/ -- Heptares has solved structures across all major GPCR families (A, B and C) providing platforms for wide-ranging structure-based and antibody drug discovery programmes Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces the publication of a scientific article describing the first high-resolution X-ray crystal...

2014-06-30 04:21:39

LONDON and BOSTON, June 30, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is delighted to announce that Fiona Marshall, Heptares' Chief Scientific Officer and co-founder, has been invited to present at the Royal Society of Medicine Medical Innovations Summit. The event, which takes place on Saturday 5 July 2014 at The Royal Society of Medicine in London, UK, will feature presentations on pioneering...

2014-06-24 12:28:56

LONDON and BOSTON, June 24, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that its President, Dan Grau, will present a company overview at the JMP Securities Healthcare Conference (24-25 June 2014, New York, NY, USA). His presentation will take place on 25 June at 9.30 am EDT. For a full list of events at which Heptares will be present, please visit http://www.heptares.com About...

2014-06-23 13:34:53

Duke University Medical Center A team of scientists from Duke Medicine, the University of Michigan and Stanford University has determined the underlying architecture of a cellular signaling complex involved in the body's response to stimuli such as light and pain. This complex, consisting of a human cell surface receptor and its regulatory protein, reveals a two-step mechanism that has been hypothesized previously but not directly documented. The findings, reported on June 22, 2014,...

2014-06-11 08:29:17

New antibodies generated with RuiYi's iCAPS technology to explore GPCR structure and function LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University announced today a new research collaboration applying RuiYi's iCAPS (Intermembranous Conformation Antigen Presenting System) technology to create novel monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to...

2014-05-29 04:22:16

LONDON and BOSTON, May 29, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Malcolm Weir, Heptares' Chief Executive Officer and co-founder, will give a company presentation at the Jefferies 2014 Global Healthcare in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 2 June. In addition, Heptares will give presentations at the following industry and scientific...

2014-05-21 16:27:02

PITTSBURGH, May 21, 2014 /PRNewswire/ -- Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer's disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH Alzheimer's Disease Drug Development Program (U01)....

2014-05-15 04:22:26

LONDON and BOSTON, May 15, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Fiona Marshall, Heptares' Chief Scientific Officer and co-founder, will give a company presentation at the UBS Global Healthcare Conference [https://www.ubs.com/global/en/investment-bank/key-investor-conferences/americas.html ] in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 19 May....

2014-04-16 04:22:10

LONDON, April 16, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Dan Grau, Heptares' President, will be attending two upcoming industry partnering and investment conferences. Mr Grau will attend the 9th Annual Neurotech Investing & Partnering Conference [https://www.regonline.com/builder/site/default.aspx?EventID=1246370 ] in Boston, MA, USA (23-24 April 2014) at which he will...

2014-03-27 08:34:12

Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi's iCAPS platform LA JOLLA, Calif. and SHANGHAI, March 27, 2014 /PRNewswire/ -- RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related